Informed Consent
Item
willing and able to give informed consent
boolean
C0021430 (UMLS CUI [1])
Age
Item
age 30 years or older at time of diagnosis of parkinson's disease
boolean
C0001779 (UMLS CUI [1])
Parkinson Disease
Item
have idiopathic parkinson's disease, defined as:
boolean
C0030567 (UMLS CUI [1])
Signs Quantity | Resting Tremor | Bradykinesia | Rigidity | Postural reflex impairment
Item
having at least 2 of the following 4 signs: resting tremor, bradykinesia, rigidity, or postural reflex impairment, at least one of which must be resting tremor or bradykinesia
boolean
C0311392 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0234379 (UMLS CUI [2])
C0233565 (UMLS CUI [3])
C0026837 (UMLS CUI [4])
C1868839 (UMLS CUI [5])
Secondary Parkinson Disease Absent | Atypical Parkinson Disease Absent
Item
no secondary or atypical parkinsonism
boolean
C0030569 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C1868596 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
Feature Asymmetric | Signs Asymmetric | Onset Asymmetric
Item
asymmetric features (current signs or history of asymmetric onset)
boolean
C2348519 (UMLS CUI [1,1])
C0332514 (UMLS CUI [1,2])
C0311392 (UMLS CUI [2,1])
C0332514 (UMLS CUI [2,2])
C0332162 (UMLS CUI [3,1])
C0332514 (UMLS CUI [3,2])
Levodopa | Disease Response Patient Self-Report
Item
response to l-dopa, by patient self-report
boolean
C0023570 (UMLS CUI [1])
C1704632 (UMLS CUI [2,1])
C0681906 (UMLS CUI [2,2])
Parkinson Disease Duration
Item
parkinson's disease duration of no more than 5 years
boolean
C0030567 (UMLS CUI [1,1])
C0449238 (UMLS CUI [1,2])
Levodopa Stable Dose U/day | Decarboxylase inhibitor Stable Dose U/day
Item
receiving stable therapy of l-dopa/dci for at least 3 months; acceptable dose range: 250 mg - 1000 mg l-dopa/dci daily
boolean
C0023570 (UMLS CUI [1,1])
C0205360 (UMLS CUI [1,2])
C0178602 (UMLS CUI [1,3])
C0456683 (UMLS CUI [1,4])
C0360140 (UMLS CUI [2,1])
C0205360 (UMLS CUI [2,2])
C0178602 (UMLS CUI [2,3])
C0456683 (UMLS CUI [2,4])
Hoehn and Yahr Stage | Levodopa Stable | Decarboxylase inhibitor Stable
Item
hoehn and yahr stage < 4 on stable l-dopa/dci treatment
boolean
C3639483 (UMLS CUI [1])
C0023570 (UMLS CUI [2,1])
C0205360 (UMLS CUI [2,2])
C0360140 (UMLS CUI [3,1])
C0205360 (UMLS CUI [3,2])
Atypical Parkinson Disease Due to Pharmaceutical Preparations | Atypical Parkinson Disease Due to Metabolic Diseases | Atypical Parkinson Disease Due to Encephalitis | Atypical Parkinson Disease Due to Neurodegenerative Disorders
Item
have atypical parkinsonism due to drugs, metabolic disorders, encephalitis, or other neurodegenerative diseases
boolean
C1868596 (UMLS CUI [1,1])
C0678226 (UMLS CUI [1,2])
C0013227 (UMLS CUI [1,3])
C1868596 (UMLS CUI [2,1])
C0678226 (UMLS CUI [2,2])
C0025517 (UMLS CUI [2,3])
C1868596 (UMLS CUI [3,1])
C0678226 (UMLS CUI [3,2])
C0014038 (UMLS CUI [3,3])
C1868596 (UMLS CUI [4,1])
C0678226 (UMLS CUI [4,2])
C0524851 (UMLS CUI [4,3])
Medical condition compromises Study Subject Participation Status | Mental condition compromises Study Subject Participation Status
Item
have any other known medical or psychiatric condition that may compromise their participation in the study
boolean
C3843040 (UMLS CUI [1,1])
C2945640 (UMLS CUI [1,2])
C2348568 (UMLS CUI [1,3])
C3840291 (UMLS CUI [2,1])
C2945640 (UMLS CUI [2,2])
C2348568 (UMLS CUI [2,3])
Investigational New Drugs
Item
have taken another investigational drug within 90 days of baseline
boolean
C0013230 (UMLS CUI [1])
Antiparkinson Agents Dose Change | Pramipexole | ropinirole | Pergolide | Bromocriptine | Methylphenidate | Anticholinergic Agents | Amantadine
Item
have a change in dosage of any other antiparkinsonian drug (eg, pramipexole, ropinirole, pergolide, bromocriptine, methylphenidate, anticholinergics, or amantadine) during the study or within 90 days prior to baseline
boolean
C0003405 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0392747 (UMLS CUI [1,3])
C0074710 (UMLS CUI [2])
C0244821 (UMLS CUI [3])
C0031007 (UMLS CUI [4])
C0006230 (UMLS CUI [5])
C0025810 (UMLS CUI [6])
C0242896 (UMLS CUI [7])
C0002403 (UMLS CUI [8])
Dopamine Antagonists | Antipsychotic Agents | Antiemetics | Dopamine Depletion Pharmaceutical Preparations | Reserpine | Tetrabenazine
Item
have received treatment with dopamine blocking agents (including neuroleptic agents, antiemetic agents), dopamine-depleting agents (including reserpine or tetrabenazine) within 90 days prior to baseline
boolean
C0242702 (UMLS CUI [1])
C0040615 (UMLS CUI [2])
C0003297 (UMLS CUI [3])
C0013030 (UMLS CUI [4,1])
C0333668 (UMLS CUI [4,2])
C0013227 (UMLS CUI [4,3])
C0035179 (UMLS CUI [5])
C0039623 (UMLS CUI [6])
Informed Consent Refused
Item
do not consent to participate
boolean
C0021430 (UMLS CUI [1,1])
C1705116 (UMLS CUI [1,2])